Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952562 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA3CHRNA7CHRM4PRKCA | |
| SCHEMBL18952560 | 1.00 | CHRNB2 (0.36) | CHRNB2CHRNA3CHRNA7CHRM4PRKCA | |
| SCHEMBL20609185 | 0.82 | KDM4E (0.35) | CHRM4PRKCAPRKCQKDM4EHTT | |
| SCHEMBL20609187 | 0.82 | KDM4E (0.35) | CHRM4PRKCAPRKCQKDM4EHTT | |
| SCHEMBL20609233 | 0.82 | KDM4E (0.35) | CHRM4PRKCAPRKCQKDM4EHTT | |
| SCHEMBL18970465 | 0.82 | KDM4E (0.35) | CHRM4PRKCAPRKCQKDM4EHTT | |
| SCHEMBL22428756 | 0.82 | KDM4E (0.35) | CHRM4PRKCAPRKCQKDM4EHTT | |
| SCHEMBL18970476 | 0.81 | PTPN11 (0.36) | CHRM4PTPN11 | |
| SCHEMBL16635304 | 0.80 | CHRNB2 (0.38) | CHRNB2CHRNA3CHRNA4CHRNB4 | |
| SCHEMBL29003148 | 0.73 | NOTUM (0.40) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | CHRNB2 666/4885CHRNA3 663/4885CHRNA7 503/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | CHRNB2 666/4885CHRNA3 663/4885CHRNA7 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.